Last updated: April 25, 2026
Who supplies oritavancin diphosphate drug substance (API) and what does the patent record show?
Public-facing supplier lists for oritavancin diphosphate (as an API) are sparse because the commercial pipeline and distribution are often handled through proprietary procurement channels, and because the active is frequently sourced from vertically integrated manufacturer networks tied to the originator’s launch and lifecycle.
What the patent landscape and regulatory history consistently indicate is that supply is controlled through a limited set of manufacturers tied to:
- Originator commercial supply
- Established contract manufacturing for sterile injectable drug product
- Niche API manufacturers supporting scale-up and lifecycle batches
However, producing a definitive “supplier list” for API requires tying specific supplier names to named regulatory submissions or patent assignments, which is not available in the information provided.
Who supplies oritavancin diphosphate drug product (sterile injectable) and what does it typically entail?
Oritavancin diphosphate is marketed as a sterile injectable. Commercial manufacturing for sterile injectables normally requires specialized capabilities that constrain the supplier set:
- A sterile drug product line for vials/infusion-bottle filling
- Aseptic processing with validated sterility assurance
- Quality systems that support parenteral release testing
- Supply-chain control for nitrogen-sparged, temperature-controlled API handling and bridging documentation
That manufacturing scope typically narrows suppliers to experienced contract manufacturing organizations (CMOs) or the originator’s internal manufacturing network.
What supplier names can be stated from the information provided?
No supplier names for oritavancin diphosphate API or sterile drug product are present in the information provided in this thread. As a result, a complete and accurate supplier list cannot be generated.
How the procurement decision should be framed for oritavancin diphosphate
With the available inputs missing supplier-identifying evidence, the only decision-ready framing is at the capability and documentation level rather than naming suppliers:
API procurement criteria (what to require)
- Demonstrated batch history for oritavancin diphosphate API under GMP
- Ability to provide CoA (assay, impurity profile, residual solvents, particle/physical specs as applicable)
- Compatibility with drug product bridging documentation for parenteral sterile manufacturing
- Traceability for sourcing and control of key intermediates
Drug product procurement criteria (what to require)
- Sterile aseptic filling for parenterals
- Validated support for lyophilized vs solution format requirements (if applicable to the commercial presentation)
- Release testing package alignment for parenteral specs
- Ability to support regulatory comparability for manufacturing changes
Key Takeaways
- A definitive supplier list for oritavancin diphosphate API and sterile injectable drug product cannot be produced from the provided information.
- The procurement scope for oritavancin diphosphate is constrained by sterile injectable manufacturing requirements and GMP-controlled API supply.
- Decision-ready sourcing should be built around documented GMP batch capability, CoA/impurity profiles, and aseptic drug product release readiness, not supplier name assumptions.
FAQs
-
Is there a universal global list of oritavancin diphosphate API suppliers?
No. Supplier disclosure is limited and often tied to specific regulatory filings and contractual relationships.
-
What manufacturing capabilities most constrain drug product supply for oritavancin diphosphate?
Sterile aseptic processing and validated parenteral filling, packaging, and release testing.
-
What documentation should be requested for API qualification?
GMP batch documentation, CoA with assay and impurity profile, residual solvents (where applicable), and traceability for controlled intermediates.
-
What does “drug product bridging” require when changing API or CMO?
Comparability work that aligns critical quality attributes and supports regulatory acceptance of manufacturing changes.
-
Why do supplier lists for complex injectables stay opaque?
Because commercial procurement frequently operates through limited qualified vendor networks and because full supplier identification is not consistently public.
Sources (APA)
[1] No sources were provided in the prompt to support supplier identification.
